
Manuel Sobrinho-SimÃues

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7953275/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Papillary thyroid carcinoma tall cell variant shares accumulation of mitochondria, mitochondrial DNA mutations, and loss of oxidative phosphorylation complex I integrity with oncocytic tumors. Journal of Pathology: Clinical Research, 2022, 8, 155-168.	3.0	10
2	The Multifaceted Profile of Thyroid Disease in the Background of DICER1 Germline and Somatic Mutations: Then, Now and Future Perspectives. Journal of Molecular Pathology, 2022, 3, 1-14.	1.2	0
3	Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocrine Pathology, 2022, 33, 27-63.	9.0	388
4	Molecular Pathology of Non-familial Follicular Epithelial–Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification. Endocrine Pathology, 2021, 32, 44-62.	9.0	24
5	Genetic Determinants for Prediction of Outcome of Patients with Papillary Thyroid Carcinoma. Cancers, 2021, 13, 2048.	3.7	16
6	Inherited Thyroid Tumors With Oncocytic Change. Frontiers in Endocrinology, 2021, 12, 691979.	3.5	4
7	Digital Pathology Workflow Implementation at IPATIMUP. Diagnostics, 2021, 11, 2111.	2.6	36
8	Cancer incidence after childhood irradiation for tinea capitis in a Portuguese cohort. British Journal of Radiology, 2020, 93, 20180677.	2.2	4
9	Comprehensive Assessment of TERT mRNA Expression across a Large Cohort of Benign and Malignant Thyroid Tumours. Cancers, 2020, 12, 1846.	3.7	11
10	S616-p-DRP1 associates with locally invasive behavior of follicular cell-derived thyroid carcinoma. Endocrine, 2020, 73, 85-97.	2.3	3
11	Molecular Aspects of Thyroid Calcification. International Journal of Molecular Sciences, 2020, 21, 7718.	4.1	24
12	Clinicopathological Features as Prognostic Predictors of Poor Outcome in Papillary Thyroid Carcinoma. Cancers, 2020, 12, 3186.	3.7	20
13	Malignant teratoid tumor of the thyroid gland: an aggressive primitive multiphenotypic malignancy showing organotypical elements and frequent DICER1 alterations—is the term "thyroblastoma―more appropriate?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 787-798.	2.8	45
14	Pitfalls in Challenging Thyroid Tumors: Emphasis on Differential Diagnosis and Ancillary Biomarkers. Endocrine Pathology, 2020, 31, 197-217.	9.0	22
15	Poorly differentiated thyroid carcinoma with pleomorphic giant cells—a case report. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 597-601.	2.8	2
16	European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. Thyroid, 2019, 29, 7-26.	4.5	122
17	Genomic and transcriptomic characterization of the mitochondrial-rich oncocytic phenotype on a thyroid carcinoma background. Mitochondrion, 2019, 46, 123-133.	3.4	10
18	New WHO classification of thyroid tumors: A pragmatic categorization of thyroid gland neoplasms. EndocrinologÃa Diabetes Y Nutrición (English Ed), 2018, 65, 133-135.	0.2	3

Manuel Sobrinho-Simões

#	Article	IF	CITATIONS
19	Nueva clasificación de la OMS de los tumores tiroideos: una categorización pragmática de las neoplasias de la glándula tiroides. Endocrinologia, Diabetes Y NutriciÓn, 2018, 65, 133-135.	0.3	16
20	Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): impact on the reclassification of thyroid nodules. Endocrine-Related Cancer, 2018, 25, R247-R258.	3.1	40
21	Multinodular Goiter Progression Toward Malignancy in a Case of DICER1 Syndrome. American Journal of Clinical Pathology, 2018, 149, 379-386.	0.7	20
22	Age-Associated Mortality Risk in Papillary Thyroid Cancer: Does BRAF Make a Real Difference?. Journal of Clinical Oncology, 2018, 36, 1455-1456.	1.6	3
23	OPNa Overexpression Is Associated with Matrix Calcification in Thyroid Cancer Cell Lines. International Journal of Molecular Sciences, 2018, 19, 2990.	4.1	16
24	Cribriform-morular variant of thyroid carcinoma: a neoplasm with distinctive phenotype associated with the activation of the WNT/l²-catenin pathway. Modern Pathology, 2018, 31, 1168-1179.	5.5	54
25	Is Low-Dose Radiation Exposure a Risk Factor for Atherosclerotic Disease?. Radiation Research, 2018, 189, 418-424.	1.5	10
26	Dynamin-Related Protein 1 at the Crossroads of Cancer. Genes, 2018, 9, 115.	2.4	67
27	Telomere Maintenance Mechanisms in Cancer. Genes, 2018, 9, 241.	2.4	91
28	CRABP1, C1QL1 and LCN2 are biomarkers of differentiated thyroid carcinoma, and predict extrathyroidal extension. BMC Cancer, 2018, 18, 68.	2.6	26
29	mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and SLC5A5 mRNA Expression. International Journal of Molecular Sciences, 2018, 19, 1448.	4.1	27
30	TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma. Endocrine, 2018, 61, 489-498.	2.3	13
31	Rare Familial Tumours. , 2018, , 57-77.		4
32	Other Rare Tumours and Tumour-Like Lesions. , 2018, , 79-105.		0
33	Rare Papillary Thyroid Carcinomas. , 2018, , 5-25.		1
34	Small Cell Tumours. , 2018, , 45-56.		0
35	Therapeutic Options. , 2018, , 107-110.		0
36	Rare Follicular Tumours. , 2018, , 27-44.		0

Manuel Sobrinho-Simões

#	Article	IF	CITATIONS
37	TERT biology and function in cancer: beyond immortalisation. Journal of Molecular Endocrinology, 2017, 58, R129-R146.	2.5	68
38	Hobnail Variant of Papillary Thyroid Carcinoma. American Journal of Surgical Pathology, 2017, 41, 854-860.	3.7	38
39	TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1898-1907.	3.6	113
40	Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer. Hormones and Cancer, 2017, 8, 314-324.	4.9	14
41	Etiopathogenesis of oncocytomas. Seminars in Cancer Biology, 2017, 47, 82-94.	9.6	11
42	TERT promoter mutations: a genetic signature of benign and malignant thyroid tumours occurring in the context of tinea capitis irradiation. European Journal of Endocrinology, 2017, 176, 49-55.	3.7	9
43	Telomerase and N-Cadherin Differential Importance in Adrenocortical Cancers and Adenomas. Journal of Cellular Biochemistry, 2017, 118, 2064-2071.	2.6	5
44	Accounting for tissue heterogeneity in infrared spectroscopic imaging for accurate diagnosis of thyroid carcinoma subtypes. Vibrational Spectroscopy, 2017, 91, 77-82.	2.2	8
45	The Genetics of Papillary Microcarcinomas of the Thyroid: Diagnostic and Prognostic Implications. Current Genomics, 2017, 18, 244-254.	1.6	25
46	Calcitonin receptor expression in medullary thyroid carcinoma. PeerJ, 2017, 5, e3778.	2.0	4
47	IL6-174 G>C Polymorphism (rs1800795) Association with Late Effects of Low Dose Radiation Exposure in the Portuguese Tinea Capitis Cohort. PLoS ONE, 2016, 11, e0163474.	2.5	5
48	Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes. Cytogenetic and Genome Research, 2016, 150, 194-207.	1.1	49
49	pmTOR is a marker of aggressiveness in papillary thyroid carcinomas. Surgery, 2016, 160, 1582-1590.	1.9	7
50	TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes. Scientific Reports, 2016, 6, 29714.	3.3	13
51	The prognostic impact of <i>TERT</i> promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism. International Journal of Cancer, 2016, 139, 414-423.	5.1	50
52	A scientific initiative born at the right place in the ideal moment. Porto Biomedical Journal, 2016, 1, 3.	1.0	0
53	Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma. European Journal of Endocrinology, 2016, 174, 551-561.	3.7	21
54	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 264-274.	3.6	179

#	Article	IF	CITATIONS
55	ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome. European Journal of Endocrinology, 2016, 174, R117-R126.	3.7	64
56	Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior. Oncotarget, 2016, 7, 52003-52016.	1.8	24
57	Thyroid and Parathyroid Glands. , 2016, , 613-671.		Ο
58	Poorly differentiated and undifferentiated thyroid carcinomas. Turk Patoloji Dergisi, 2015, 31 Suppl 1, 48-59.	0.3	16
59	OXPHOS dysfunction regulates integrin-Â1 modifications and enhances cell motility and migration. Human Molecular Genetics, 2015, 24, 1977-1990.	2.9	35
60	Next-Generation Pathology—Surveillance of Tumor Microecology. Journal of Molecular Biology, 2015, 427, 2013-2022.	4.2	17
61	RE: TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma. Journal of the National Cancer Institute, 2015, 107, djv049-djv049.	6.3	3
62	Coexistence of <i>TERT</i> Promoter and <i>BRAF</i> Mutations in Papillary Thyroid Carcinoma: Added Value in Patient Prognosis?. Journal of Clinical Oncology, 2015, 33, 667-668.	1.6	36
63	Mitochondrial Dynamics Protein Drp1 Is Overexpressed in Oncocytic Thyroid Tumors and Regulates Cancer Cell Migration. PLoS ONE, 2015, 10, e0122308.	2.5	151
64	Differentiated thyroid cancer in patients with resistance to thyroid hormone syndrome. A novel case and a review of the literature. Frontiers in Molecular Biosciences, 2014, 1, 10.	3.5	11
65	Thyroid and parathyroid tumours in patients submitted to X-ray scalp epilation during the tinea capitis eradication campaign in the North of Portugal (1950–1963). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 445-452.	2.8	10
66	Small Cell Tumors of the Thyroid Gland. International Journal of Surgical Pathology, 2014, 22, 197-201.	0.8	15
67	C-Cell-Derived Calcitonin-Free Neuroendocrine Carcinoma of the Thyroid. International Journal of Surgical Pathology, 2014, 22, 530-535.	0.8	32
68	Carcinoma of the Thyroid With Ewing/PNET Family Tumor Elements. International Journal of Surgical Pathology, 2014, 22, 579-581.	0.8	18
69	Carcinoma of the Thyroid With Ewing Family Tumor Elements and Favorable Prognosis. International Journal of Surgical Pathology, 2014, 22, 260-265.	0.8	25
70	Prognostic biomarkers in thyroid cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 333-346.	2.8	49
71	A Polymorphism in the Promoter Region of the Selenoprotein S Gene (<i>SEPS1</i>) Contributes to Hashimoto's Thyroiditis Susceptibility. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E719-E723.	3.6	63
72	Papillary Thyroid Microcarcinoma. International Journal of Surgical Pathology, 2014, 22, 113-119.	0.8	41

#	Article	IF	CITATIONS
73	PNET with neuroendocrine differentiation of the lung. International Journal of Surgical Pathology, 2014, 22, 427-433.	0.8	9
74	Oncocytic Lesions of the Thyroid, Kidney, Salivary Glands, Adrenal Cortex, and Parathyroid Glands. International Journal of Surgical Pathology, 2014, 22, 33-36.	0.8	39
75	mTOR activation in medullary thyroid carcinoma with RAS mutation. European Journal of Endocrinology, 2014, 171, 633-640.	3.7	31
76	Telomerase promoter mutations in cancer: an emerging molecular biomarker?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 119-133.	2.8	104
77	Increased lymphangiogenesis in Riedel thyroiditis (Immunoglobulin G4-related thyroid disease). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 359-364.	2.8	11
78	TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E754-E765.	3.6	451
79	TERT Promoter Mutations in Skin Cancer: The Effects of Sun Exposure and X-Irradiation. Journal of Investigative Dermatology, 2014, 134, 2251-2257.	0.7	105
80	Polymorphisms in the TNFA and IL6 Genes Represent Risk Factors for Autoimmune Thyroid Disease. PLoS ONE, 2014, 9, e105492.	2.5	33
81	Effect of miR-128 in DNA Damage of HL-60 Acute Myeloid Leukemia Cells. Current Pharmaceutical Biotechnology, 2014, 15, 492-502.	1.6	21
82	Frequency of TERT promoter mutations in human cancers. Nature Communications, 2013, 4, 2185.	12.8	740
83	Stimulated Thyroglobulin at Recombinant Human TSH-Aided Ablation Predicts Disease-free Status One Year Later. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4364-4372.	3.6	38
84	A founder SDHB mutation in Portuguese paraganglioma patients. Endocrine-Related Cancer, 2013, 20, L23-L26.	3.1	12
85	MEN1 intragenic deletions may represent the most prevalent somatic event in sporadic primary hyperparathyroidism. European Journal of Endocrinology, 2013, 168, 119-128.	3.7	28
86	Genetic alterations in thyroid tumors from patients irradiated in childhood for tinea capitis treatment. European Journal of Endocrinology, 2013, 169, 673-679.	3.7	9
87	Reply to †The new molecular markers DDIT3, STT3A, ARG2 and FAM129A are not useful in diagnosing thyroid follicular tumors'. Modern Pathology, 2013, 26, 613-615.	5.5	0
88	Human papillomaviruses in intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva. European Journal of Cancer Prevention, 2013, 22, 566-568.	1.3	17
89	Cribriform-Morular Variant of Papillary Thyroid Carcinoma Displaying Poorly Differentiated Features. International Journal of Surgical Pathology, 2013, 21, 379-389.	0.8	34
90	Diagnostic and prognostic implications of the <i><scp>PAX</scp>8–<scp>PPAR</scp>γ</i> translocation in thyroid carcinomas—a <scp>TMA</scp> â€based study of 226 cases. Histopathology, 2013, 63, 234-241.	2.9	31

#	Article	IF	CITATIONS
91	Neuroendocrine markers and sustentacular cell count in benign and malignant pheochromocytomas – a comparative study. Polish Journal of Pathology, 2013, 2, 129-135.	0.3	17
92	Endoscopic Ultrasonographic Features of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma with a â€̃Pseudocircumvolutory' Appearance. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 687-688.	1.7	0
93	Absence of theBRAFand theGRIM-19Mutations in Oncocytic (Hürthle Cell) Solid Cell Nests of the Thyroid. American Journal of Clinical Pathology, 2012, 137, 612-618.	0.7	17
94	The new molecular markers DDIT3, STT3A, ARG2 and FAM129A are not useful in diagnosing thyroid follicular tumors. Modern Pathology, 2012, 25, 537-547.	5.5	16
95	C-Cell Hyperplasia and Papillary Thyroid Carcinoma. International Journal of Surgical Pathology, 2012, 20, 643-644.	0.8	2
96	STAT3 negatively regulates thyroid tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2361-70.	7.1	110
97	CDX2 Expression in Some Variants of Papillary Thyroid Carcinoma. American Journal of Clinical Pathology, 2012, 138, 907-910.	0.7	10
98	The biology and the genetics of Hürthle cell tumors of the thyroid. Endocrine-Related Cancer, 2012, 19, R131-R147.	3.1	76
99	Survey of 548 oncogenic fusion transcripts in thyroid tumors supports the importance of the already established thyroid fusions genes. Genes Chromosomes and Cancer, 2012, 51, 1154-1164.	2.8	20
100	mTOR Pathway Overactivation in BRAF Mutated Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1139-E1149.	3.6	66
101	<i>RET/PTC</i> rearrangement is prevalent in follicular Hürthle cell carcinomas. Histopathology, 2012, 61, 833-843.	2.9	42
102	AZD1480 Blocks Growth and Tumorigenesis of RET- Activated Thyroid Cancer Cell Lines. PLoS ONE, 2012, 7, e46869.	2.5	20
103	Follicular thyroid carcinoma. Modern Pathology, 2011, 24, S10-S18.	5.5	127
104	Head and neck lesions in a cohort irradiated in childhood for tinea capitis treatment. Lancet Infectious Diseases, The, 2011, 11, 163-164.	9.1	14
105	Tumor-in-Tumor of the Thyroid With Basaloid Differentiation: A Lesion With a Solid Cell Nest Neoplastic Component?. International Journal of Surgical Pathology, 2011, 19, 276-280.	0.8	18
106	The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 265-276.	2.8	47
107	Poorly differentiated thyroid carcinoma: an evolving entity. Diagnostic Histopathology, 2011, 17, 114-123.	0.4	20
108	How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer. Journal of Thyroid Research, 2011, 2011, 1-10.	1.3	17

#	Article	IF	CITATIONS
109	In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp. Endocrine-Related Cancer, 2011, 18, 401-412.	3.1	11
110	Small-Cell (Basaloid) Thyroid Carcinoma. International Journal of Surgical Pathology, 2011, 19, 620-626.	0.8	25
111	Small papillary thyroid cancers—is BRAF of prognostic value?. Nature Reviews Endocrinology, 2011, 7, 9-10.	9.6	19
112	In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood, 2010, 116, 1329-1335.	1.4	78
113	Molecular Pathology of Thyroid Tumors: Diagnostic and Prognostic Relevance. International Journal of Surgical Pathology, 2010, 18, 209-212.	0.8	6
114	Hot Topics in Papillary Thyroid Carcinoma. International Journal of Surgical Pathology, 2010, 18, 190-193.	0.8	1
115	Review Article: The Familial Counterparts of Follicular Cell—Derived Thyroid Tumors. International Journal of Surgical Pathology, 2010, 18, 233-242.	0.8	7
116	Cribriform-Morular Variant of Papillary Thyroid Carcinoma. American Journal of Clinical Pathology, 2009, 131, 134-142.	0.7	68
117	Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer, 2009, 9, 387.	2.6	24
118	Mitochondria and cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 481-495.	2.8	46
119	A follicular variant of papillary thyroid carcinoma in struma ovarii. Case report with unique molecular alterations. Histopathology, 2009, 55, 482-487.	2.9	20
120	Is <i>BRAF</i> mutation screening useful for preoperative risk stratification in papillary thyroid cancer?. Future Oncology, 2009, 5, 1225-1229.	2.4	4
121	BRAF mutation in solid cell nest hyperplasia associated with papillary thyroid carcinoma. A precursor lesion?. Human Pathology, 2009, 40, 1029-1035.	2.0	33
122	BRAF ^{V600E} mutation in papillary thyroid carcinoma: a potential target for therapy?. Expert Review of Endocrinology and Metabolism, 2009, 4, 467-480.	2.4	0
123	Acquisition of <i>BRAF</i> gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma. Clinical Endocrinology, 2008, 69, 683-685.	2.4	27
124	Intragenic Mutations in Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2008, 37, 333-362.	3.2	87
125	Follicular thyroid carcinoma with an unusual glomeruloid pattern of growth. Human Pathology, 2008, 39, 1540-1547.	2.0	15
126	GRIM-19 in Health and Disease. Advances in Anatomic Pathology, 2008, 15, 46-53.	4.3	20

#	Article	IF	CITATIONS
127	High Frequency of Germline Succinate Dehydrogenase Mutations in Sporadic Cervical Paragangliomas in Northern Spain: Mitochondrial Succinate Dehydrogenase Structure-Function Relationships and Clinical-Pathological Correlations. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4853-4864.	3.6	51
128	Poorly Differentiated Thyroid Carcinoma: The Turin Proposal for the Use of Uniform Diagnostic Criteria and an Algorithmic Diagnostic Approach. American Journal of Surgical Pathology, 2007, 31, 1256-1264.	3.7	521
129	Molecular and Genotypic Characterization of Human Thyroid Follicular Cell Carcinoma–Derived Cell Lines. Thyroid, 2007, 17, 707-715.	4.5	81
130	Molecular genetics of papillary thyroid carcinoma: great expectations Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 643-653.	1.3	28
131	The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma. Human Pathology, 2006, 37, 562-568.	2.0	26
132	B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Human Pathology, 2006, 37, 781-786.	2.0	72
133	Diagnostic Criteria in Well-Differentiated Thyroid Carcinomas. Endocrine Pathology, 2006, 17, 109-118.	9.0	31
134	Warthin's tumour. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 448, 877-878.	2.8	7
135	BRAF Mutations in Thyroid Carcinomas: Phenotype-Genotype Correlations. Advances in Anatomic Pathology, 2005, 12, 106-107.	4.3	Ο
136	Hereditary Diffuse Gastric Cancer: Lessons from Histopathology. Advances in Anatomic Pathology, 2005, 12, 151-152.	4.3	4
137	Molecular pathology of well-differentiated thyroid carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 447, 787-793.	2.8	67
138	Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 589-595.	2.8	242
139	Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes. Journal of Pathology, 2005, 206, 305-311.	4.5	38
140	A Subset of the Follicular Variant of Papillary Thyroid Carcinoma Harbors the PAX8-PPARÎ ³ Translocation. International Journal of Surgical Pathology, 2005, 13, 235-238.	0.8	39
141	Cystic Tumor of the Atrioventricular Node of the Heart Appears to Be the Heart Equivalent of the Solid Cell Nests (Ultimobranchial Rests) of the Thyroid. American Journal of Clinical Pathology, 2005, 123, 369-375.	0.7	32
142	Hürthle (Oncocytic) Cell Tumors of Thyroid: Etiopathogenesis, Diagnosis and Clinical Significance. International Journal of Surgical Pathology, 2005, 13, 29-35.	0.8	67
143	Mitochondrial D-Loop instability in thyroid tumours is not a marker of malignancy. Mitochondrion, 2005, 5, 333-340.	3.4	28
144	A stem cell role for thyroid solid cell nests. Human Pathology, 2005, 36, 590-591.	2.0	26

#	Article	IF	CITATIONS
145	A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Human Pathology, 2005, 36, 694-697.	2.0	93
146	Diagnostic pitfalls of thyroid pathology. Current Diagnostic Pathology, 2005, 11, 52-59.	0.4	15
147	Reply to: Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Letters, 2005, 230, 149-150.	7.2	4
148	Cystic Tumor of the Atrioventricular Node of the Heart Appears to Be the Heart Equivalent of the Solid Cell Nests (Ultimobranchial Rests) of the Thyroid. American Journal of Clinical Pathology, 2005, 123, 369-375.	0.7	6
149	Telomerase expression and proliferative activity suggest a stem cell role for thyroid solid cell nests. Modern Pathology, 2004, 17, 819-826.	5.5	57
150	Core I gene is overexpressed in Hürthle and non-Hürthle cell microfollicular adenomas and follicular carcinomas of the thyroid. BMC Cancer, 2004, 4, 12.	2.6	4
151	BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 572-6.	2.8	108
152	BRAF mutations are associated with some histological types of papillary thyroid carcinoma. Journal of Pathology, 2004, 202, 247-251.	4.5	334
153	Model of the early development of diffuse gastric cancer in E adherin mutation carriers and its implications for patient screening. Journal of Pathology, 2004, 203, 681-687.	4.5	242
154	BRAFMutations Are Not a Major Event in Post-Chernobyl Childhood Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4267-4271.	3.6	171
155	Observer Variation in the Diagnosis of Follicular Variant of Papillary Thyroid Carcinoma. American Journal of Surgical Pathology, 2004, 28, 1336-1340.	3.7	456
156	Hyalinizing trabecular tumor of the thyroid displaying neuroendocrine differentiation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, -1, 1-1.	2.8	1
157	Letter to the editor. Genes Chromosomes and Cancer, 2003, 36, 318-318.	2.8	5
158	BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene, 2003, 22, 4578-4580.	5.9	616
159	p63 Expression in Solid Cell Nests of the Thyroid: Further Evidence for a Stem Cell Origin. Modern Pathology, 2003, 16, 43-48.	5.5	106
160	A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology, 2003, 125, 364-371.	1.3	450
161	Renaming Papillary Microcarcinoma of the Thyroid Gland: The Porto Proposal. International Journal of Surgical Pathology, 2003, 11, 249-251.	0.8	140
162	WNT-inducible signaling pathway protein 3, WISP-3, is mutated in microsatellite unstable gastrointestinal carcinomas but not in endometrial carcinomas. Gastroenterology, 2003, 124, 270-271.	1.3	11

#	Article	IF	CITATIONS
163	Vascular Invasion in Thyroid and Gastric Carcinomas. Ultrastructural Pathology, 2003, 27, 41-48.	0.9	1
164	Germline Succinate Dehydrogenase Subunit D Mutation Segregating with Familial Non-RET C Cell Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4932-4937.	3.6	25
165	Helicobacter pylori and Interleukin 1 Genotyping: An Opportunity to Identify High-Risk Individuals for Gastric Carcinoma. Journal of the National Cancer Institute, 2002, 94, 1680-1687.	6.3	563
166	Different Types of Epithelial Cadherin Alterations Play Different Roles in Human Carcinogenesis. Advances in Anatomic Pathology, 2002, 9, 329-337.	4.3	6
167	Mitochondrial DNA Somatic Mutations (Point Mutations and Large Deletions) and Mitochondrial DNA Variants in Human Thyroid Pathology. American Journal of Pathology, 2002, 160, 1857-1865.	3.8	243
168	Poorly Differentiated Carcinomas of the Thyroid Gland. International Journal of Surgical Pathology, 2002, 10, 123-131.	0.8	68
169	Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immunohistochemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2002. 440. 418-424.	2.8	90
170	Mucoepidermoid carcinoma of the thyroid: a tumour histotype characterised by P-cadherin neoexpression and marked abnormalities of E-cadherin/catenins complex. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2002, 440, 498-504.	2.8	31
171	Mucins as key molecules for the classification of intestinal metaplasia of the stomach. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2002, 440, 311-317.	2.8	60
172	Expression of mucins (MUC1, MUC2, MUC5AC, and MUC6) and type 1 Lewis antigens in cases with and withoutHelicobacter pyloricolonization in metaplastic glands of the human stomach. Journal of Pathology, 2002, 197, 37-43.	4.5	46
173	Follicular, Papillary, and "Hybrid" Carcinomas of the Thyroid. Endocrine Pathology, 2002, 13, 313-320.	9.0	27
174	Difficult Cases of Thyroid Pathology. Endocrine Pathology, 2002, 13, 369-372.	9.0	1
175	Surgical Pathology Versus Molecular Biology. International Journal of Surgical Pathology, 2001, 9, 1-3.	0.8	3
176	Abnormalities of the E-cadherin/catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant. Journal of Pathology, 2001, 194, 358-366.	4.5	65
177	Microsatellite instability, mitochondrial DNA large deletions, and mitochondrial DNA mutations in gastric carcinoma. Genes Chromosomes and Cancer, 2001, 32, 136-143.	2.8	99
178	Early Gastric Stump Carcinoma with Rhabdoid Features. Pathology Research and Practice, 2001, 197, 93-94.	2.3	0
179	Fetal adenomas and minimally invasive follicular carcinomas of the thyroid frequently display a triploid or near triploid DNA pattern. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 438, 336-342.	2.8	20
180	Somatic but Not Germline Mutation of the <i>APC</i> Gene in a Case of Cribriform-Morular Variant of Papillary Thyroid Carcinoma. American Journal of Clinical Pathology, 2001, 115, 486-493.	0.7	74

#	Article	IF	CITATIONS
181	The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. , 2000, 88, 238-239.		25
182	Hail to the histologic grading of papillary thyroid carcinoma?. , 2000, 88, 1766-1768.		6
183	Gastric carcinoma exhibits distinct types of cell differentiation: an immunohistochemical study of trefoil peptides (TFF1 and TFF2) and mucins (MUC1, MUC2, MUC5AC, and MUC6). , 2000, 190, 437-443.		135
184	Mitochondrial DNA ?common? deletion in Hïż¹⁄2rthle cell lesions of the thyroid. Journal of Pathology, 2000, 192, 561-562.	4.5	53
185	MSI-L Gastric Carcinomas Share the hMLH1 Methylation Status of MSI-H Carcinomas but Not Their Clinicopathological Profile. Laboratory Investigation, 2000, 80, 1915-1923.	3.7	43
186	Recommended Reporting Format for Thyroid Carcinoma. American Journal of Clinical Pathology, 2000, 114, 684-686.	0.7	3
187	Immunohistochemical Study of the Expression of MUC6 Mucin and Co-expression of Other Secreted Mucins (MUC5AC and MUC2) in Human Gastric Carcinomas. Journal of Histochemistry and Cytochemistry, 2000, 48, 377-388.	2.5	142
188	Clinicopathologic and prognostic significance of the expression of mucins, simple mucin antigens and histoblood group antigens in papillary thyroid carcinoma. Endocrine Pathology, 1999, 10, 305-313.	9.0	7
189	Papillary thyroid carcinoma overexpresses fully and underglycosylated mucins together with native and sialylated simple mucin antigens and histo-blood group antigens. Endocrine Pathology, 1999, 10, 315-324.	9.0	12
190	Mucins and mucin-associated carbohydrate antigens expression in gastric carcinoma cell lines. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1999, 435, 479-485.	2.8	24
191	Microsatellite instability in hyperplastic and adenomatous polyps of the stomach. , 1999, 86, 1649-1656.		37
192	Patterns of expression of trefoil peptides and mucins in gastric polyps with and without malignant transformation. , 1999, 187, 541-548.		47
193	Cytomorphologic Features of Mucoepidermoid Carcinoma of the Thyroid. American Journal of Clinical Pathology, 1999, 111, 134-135.	0.7	6
194	Microsatellite instability in hyperplastic and adenomatous polyps of the stomach. Cancer, 1999, 86, 1649-1656.	4.1	1
195	Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma. , 1998, 79, 402-410.		104
196	Sporadicret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms?. , 1998, 185, 71-78.		110
197	Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. , 1998, 21, 101-107.		203
198	The Clinicopathological Features of Gastric Carcinomas with Microsatellite Instability May Be Mediated by Mutations of Different "Target Genes― American Journal of Pathology, 1998, 153, 1211-1219.	3.8	144

#	Article	IF	CITATIONS
199	Synovial sarcoma. Evaluation of Prognosis with Emphasis on the Study of DNA Ploidy and Proliferation (PCNA and Ki-67) Markers. Analytical Cellular Pathology, 1998, 16, 45-62.	2.1	31
200	Sporadic retâ€rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms?. Journal of Pathology, 1998, 185, 71-78.	4.5	9
201	Cytologic Features of Fine Needle Aspirates of Papillary and Mucoepidermoid Carcinoma of the Thyroid with Anaplastic Transformation. Acta Cytologica, 1997, 41, 1356-1360.	1.3	21
202	Carbohydrate antigens as oncofetal antigens in papillary carcinoma of the thyroid gland. Endocrine Pathology, 1997, 8, 301-303.	9.0	7
203	Pattern of expression of intermediate cytokeratin filaments in the thyroid gland: an immunohistochemical study of simple and stratified epithelial-type cytokeratins. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1997, 430, 239-245.	2.8	71
204	LETTER TO THE EDITOR. Relationship between the expression of p53 and the aggressiveness of gastric carcinoma. , 1997, 181, 349-349.		1
205	Ki67 LABELLING INDEX IN GASTRIC CARCINOMAS. AN IMMUNOHISTOCHEMICAL STUDY USING DOUBLE STAINING FOR THE EVALUATION OF THE PROLIFERATIVE ACTIVITY OF DIFFUSE-TYPE CARCINOMAS. , 1997, 182, 62-67.		37
206	Assessment of microsatellite alterations in young patients with gastric adenocarcinoma. Cancer, 1997, 80, 1357-1362.	4.1	2
207	E-cadherin gene alterations are rare events in thyroid tumors. , 1997, 70, 32-38.		81
208	Immunohistochemical study of MUC5AC expression in human gastric carcinomas using a novel monoclonal antibody. , 1997, 74, 112-121.		172
209	Ki67 LABELLING INDEX IN GASTRIC CARCINOMAS. AN IMMUNOHISTOCHEMICAL STUDY USING DOUBLE STAINING FOR THE EVALUATION OF THE PROLIFERATIVE ACTIVITY OF DIFFUSEâ€TYPE CARCINOMAS. Journal of Pathology, 1997, 182, 62-67.	4.5	3
210	Do cathepsins play a role in the biological behavior of gastric carcinoma?. Human Pathology, 1996, 27, 997-998.	2.0	1
211	Expression of simple mucin type antigens and Lewis type 1 and type 2 chain antigens in the thyroid gland: An immunohistochemical study of normal thyroid tissues, benign lesions, and malignant tumors. Endocrine Pathology, 1996, 7, 291-301.	9.0	10
212	Poorly differentiated carcinomas of the thyroid. Endocrine Pathology, 1996, 7, 99-102.	9.0	35
213	Sialosyl Tn antigen expression is associated with the prognosis of patients with advanced gastric cancer. , 1996, 78, 177-178.		4
214	Prognostic significance of T antigen expression in patients with gastric carcinoma. , 1996, 78, 2448-2449.		2
215	Sporadic gastric carcinomas with microsatellite instability display a particular clinicopathologic profile. International Journal of Cancer, 1995, 64, 32-36.	5.1	110
216	Increasing levels of MYC and MET co-amplification during tumor progression of a case of gastric cancer. Cancer Genetics and Cytogenetics, 1995, 82, 140-145.	1.0	45

#	Article	IF	CITATIONS
217	Carcinoma arising in gastric hyperplastic polyps. Gastrointestinal Endoscopy, 1995, 41, 178-179.	1.0	11
218	Expression of laminin, collagen IV, fibronectin, and type IV collagenase in gastric carcinoma. Cancer, 1994, 73, 518-527.	4.1	84
219	An Immunohistochemical study of ras oncoprotein expression in gastric carcinoma. Cancer, 1994, 73, 2010-2012.	4.1	5
220	Correspondence. Cancer, 1994, 73, 2879-2881.	4.1	12
221	Expression of C-erb B2 in tumours and tumour-like lesions of the thyroid. International Journal of Cancer, 1994, 56, 459-461.	5.1	12
222	p53 alterations in gastric carcinoma:. Cancer Genetics and Cytogenetics, 1994, 75, 45-50.	1.0	14
223	Solid cell nests of the thyroid: Light microscopy and immunohistochemical profileâ [~] †. Human Pathology, 1994, 25, 684-693.	2.0	79
224	Solitary Fibrous Tumor of the Thyroid. American Journal of Clinical Pathology, 1994, 101, 535-538.	0.7	125
225	Hyperplastic polyposis and diffuse carcinoma of the stomach. A study of a family. Cancer, 1993, 72, 323-329.	4.1	53
226	CDw75 Antigen expression in human gastric carcinoma and adjacent mucosa. Cancer, 1993, 72, 1522-1527.	4.1	13
227	Letters to the editor. World Journal of Surgery, 1993, 17, 417-418.	1.6	3
228	Solitary fibrous tumour of the thyroid: Clinicopathological, immunohistochemical and ultrastructural study of three cases. Virchows Archiv A, Pathological Anatomy and Histopathology, 1993, 422, 491-497.	1.4	86
229	Immunohistochemical expression of oncofetal fibronectin in benign and malignant lesions of the stomach. European Journal of Cancer, 1993, 29, 2070-2071.	2.8	17
230	Cytogenetic findings in eleven gastric carcinomas. Cancer Genetics and Cytogenetics, 1993, 68, 42-48.	1.0	53
231	The Ultrastructural Spectrum of Synovial Sarcomas: A Study of the Epithelial Type Differentiation of Primary Tumors, Recurrences, and Metastases. Ultrastructural Pathology, 1993, 17, 137-151.	0.9	16
232	Signet Ring Cell Carcinoma of the Stomach: A Morphometric, Ultrastructural, and DNA Cytometric Study. Ultrastructural Pathology, 1992, 16, 603-614.	0.9	22
233	Epithelial degeneration induced by Helicobacter pylori. Human Pathology, 1992, 23, 1314-1315.	2.0	6
234	Loss of Y chromosome in gastric carcinoma. Cancer Genetics and Cytogenetics, 1992, 61, 39-41.	1.0	18

#	Article	IF	CITATIONS
235	Isochromosome 8q. Cancer Genetics and Cytogenetics, 1991, 54, 137-138.	1.0	14
236	Familial gastric polyposis revisited. Cancer Genetics and Cytogenetics, 1991, 53, 97-100.	1.0	28
237	Round cell sarcoma after clear cell sarcoma remission. European Journal of Cancer & Clinical Oncology, 1991, 27, 1187.	0.7	Ο
238	Hyalinizing trabecular adenoma: A misnomer for a peculiar tumor of the thyroid gland. Endocrine Pathology, 1991, 2, 83-91.	9.0	75
239	Thyroid oncology: The end of the dogmas. Endocrine Pathology, 1991, 2, 117-119.	9.0	6
240	The Saga of Rhabdoid Cells and Rhabdoid Tumors. Ultrastructural Pathology, 1991, 15, iii-v.	0.9	4
241	Intracytoplasmic Bodies in the Myocardium: Case for the Panel. Ultrastructural Pathology, 1988, 12, 357-363.	0.9	1
242	What's Going on in Nerve Sheath Tumors?. Ultrastructural Pathology, 1988, 12, iii-iv.	0.9	0
243	Columnar-Cell Carcinoma: Another Variant of Poorly Differentiated Carcinoma of the Thyroid. American Journal of Clinical Pathology, 1988, 89, 264-267.	0.7	144
244	Prognosis in Gastric Carcinoma The preeminence of staging and futility of histological classification. , 1988, , 51-68.		17
245	Ultrastructural Appearance of Amyloid. Ultrastructural Pathology, 1987, 11, 67-77.	0.9	5
246	Letters to the Case. Pathology Research and Practice, 1986, 181, 765.	2.3	0
247	Concurrent Production of Calcitonin and Thyreoglobulin by the Same Neoplastic Cells. Ultrastructural Pathology, 1986, 10, 241-248.	0.9	28
248	Medullary Carcinoma of the Thyroid Gland: An Immunocytochemical Study. Ultrastructural Pathology, 1985, 8, 25-41.	0.9	79
249	Farewell to the Dual Histogenesis of Thyroid Tumors?. Ultrastructural Pathology, 1985, 8, iii-v.	0.9	11
250	Anomalous papillary carcinoma of the thyroid. Cancer, 1983, 51, 1462-1467.	4.1	13
251	Ultrastructural Morphometry of Thyroid Neoplasms. American Journal of Clinical Pathology, 1983, 79, 166-171.	0.7	25
252	The Diagnostic Value of Flow Cytometric DNA Measurements in Selected Disorders of the Human Thyroid. American Journal of Clinical Pathology, 1982, 77, 20-25.	0.7	87

#	Article	IF	CITATIONS
253	Papillary carcinomas of the thyroid have pore-deficient nuclei. International Journal of Cancer, 1982, 30, 409-411.	5.1	14
254	Plasmacytoid myoepithelioma of the palate. A case report with ultrastructural findings and review of the literature. Journal of Oral Pathology and Medicine, 1981, 10, 14-21.	2.7	26
255	The Diagnostic Significance of Intracytoplasmic Lumina in Metastatic Neoplasms. Ultrastructural Pathology, 1981, 2, 327-335.	0.9	40